PUBLICATION

Pharmacological HIF2? inhibition improves VHL disease?associated phenotypes in zebrafish model

Authors
Martins Metelo, A., Noonan, H.R., Xiang, L., Jin, Y., Baker, R., Kamentsky, L., Zhang, Y., van Rooijen, E., Shin, J., Carpenter, A.E., Yeh, J.R., Peterson, R.T., Iliopoulos, O.
ID
ZDB-PUB-150414-6
Date
2015
Source
J. Clin. Invest.   125(5): 1987-97 (Journal)
Registered Authors
Peterson, Randall, Shin, Jordan, van Rooijen, Ellen, Yeh, Jing-Ruey (Joanna)
Keywords
none
MeSH Terms
  • Drug Evaluation, Preclinical
  • Sulfones/pharmacology
  • Sulfones/therapeutic use*
  • Myocardial Contraction/drug effects
  • Humans
  • Hydrazones/pharmacology
  • Hydrazones/therapeutic use*
  • 5' Untranslated Regions
  • von Hippel-Lindau Disease/drug therapy*
  • von Hippel-Lindau Disease/genetics
  • von Hippel-Lindau Disease/pathology
  • von Hippel-Lindau Disease/physiopathology
  • Phenotype
  • Zebrafish Proteins/deficiency
  • Zebrafish Proteins/genetics
  • Liver/pathology
  • Zebrafish/embryology
  • Zebrafish/genetics
  • Basic Helix-Loop-Helix Transcription Factors/antagonists & inhibitors*
  • Basic Helix-Loop-Helix Transcription Factors/deficiency
  • Basic Helix-Loop-Helix Transcription Factors/genetics
  • Neovascularization, Pathologic/drug therapy
  • Neovascularization, Pathologic/genetics
  • Retinal Vessels/pathology
  • Embryo, Nonmammalian
  • Amino Acids, Dicarboxylic/toxicity
  • Animals
  • Kidney/pathology
  • Polycythemia/drug therapy
  • Polycythemia/genetics
  • Hypoxia-Inducible Factor 1, alpha Subunit/deficiency
  • Hypoxia-Inducible Factor 1, alpha Subunit/genetics
  • Gene Expression Regulation/drug effects
  • Tumor Suppressor Proteins/deficiency
  • Tumor Suppressor Proteins/genetics
  • Brain/blood supply
  • Disease Models, Animal
(all 37)
PubMed
25866969 Full text @ J. Clin. Invest.
Abstract
Patients with a germline mutation in von Hippel-Lindau (VHL) develop renal cell cancers and hypervascular tumors of the brain, adrenal glands, and pancreas as well as erythrocytosis. These phenotypes are driven by aberrant expression of HIF2α, which induces expression of genes involved in cell proliferation, angiogenesis, and red blood cell production. Currently, there are no effective treatments available for VHL disease. Here, using an animal model of VHL, we report a marked improvement of VHL-associated phenotypes following treatment with HIF2α inhibitors. Inactivation of vhl in zebrafish led to constitutive activation of HIF2α orthologs and modeled several aspects of the human disease, including erythrocytosis, pathologic angiogenesis in the brain and retina, and aberrant kidney and liver proliferation. Treatment of vhl-/- mutant embryos with HIF2α-specific inhibitors downregulated Hif target gene expression in a dose-dependent manner, improved abnormal hematopoiesis, and substantially suppressed erythrocytosis and angiogenic sprouting. Moreover, pharmacologic inhibition of HIF2α reversed the compromised cardiac contractility of vhl-/- embryos and partially rescued early lethality. This study demonstrates that small-molecule targeting of HIF2α improves VHL-related phenotypes in a vertebrate animal model and supports further exploration of this strategy for treating VHL disease.
Genes / Markers
Figures
No images available
Show all Figures
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Antibodies
Orthology
Engineered Foreign Genes
Mapping
Your Input Welcome
We welcome your input and comments. Please use this form to recommend updates to the information in ZFIN. We appreciate as much detail as possible and references as appropriate. We will review your comments promptly.
Citation
Martins Metelo, A., Noonan, H.R., Xiang, L., Jin, Y., Baker, R., Kamentsky, L., Zhang, Y., van Rooijen, E., Shin, J., Carpenter, A.E., Yeh, J.R., Peterson, R.T., Iliopoulos, O. (2015) Pharmacological HIF2? inhibition improves VHL disease?associated phenotypes in zebrafish model. J. Clin. Invest.. 125(5):1987-97.